| Names | |
|---|---|
| Preferred IUPAC name | (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide acetate |
| Other names | Pitocin Syntocinon Oxytocic Hormone Oxytoxin Oxytocinum |
| Pronunciation | /ˌɒk.sɪˈtəʊ.sɪn ˈæs.ɪ.teɪt ɪnˈdʒɛk.ʃən/ |
| Identifiers | |
| CAS Number | 50-56-6 |
| Beilstein Reference | 4479 |
| ChEBI | CHEBI:7872 |
| ChEMBL | CHEMBL3996530 |
| ChemSpider | 3447372 |
| DrugBank | DB00107 |
| ECHA InfoCard | 03f62f87-4f19-406a-9bc9-8b756c97e8be |
| EC Number | 1.21.3.1 |
| Gmelin Reference | Gmelin Reference: 177777 |
| KEGG | D11086 |
| MeSH | D03AEA1SD9 |
| PubChem CID | 439302 |
| RTECS number | GV7875000 |
| UNII | 7T39NWG09B |
| UN number | UN3249 |
| CompTox Dashboard (EPA) | DTXSID1024295 |
| Properties | |
| Chemical formula | C43H66N12O12S2 |
| Molar mass | 1007.19 g/mol |
| Appearance | Colorless clear liquid |
| Odor | Odorless |
| Density | 1.03 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -4.7 |
| Acidity (pKa) | 9.0 |
| Basicity (pKb) | 7.74 |
| Dipole moment | 0 D |
| Pharmacology | |
| ATC code | G02CB01 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Prescription only; For intravenous or intramuscular use; Dilute before use; Store below 25°C; Protect from light; Single-use vial; Keep out of reach of children. |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Do not use if the solution is discolored or contains particulate matter. For single use only. Discard unused portion. Use with caution in patients with cardiovascular disorders. Use only as directed by a physician. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 0, Instability: 0, Special: - |
| Explosive limits | Non-explosive |
| LD50 (median dose) | LD50 (mouse, IV): 0.7 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | REL=30 months |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Oxytocin Carbetocin Desmopressin Vasopressin Terlipressin Pitocin Demoxytocin |
| Property | Industrial Commentary |
|---|---|
| Product Name | Oxytocin Acetate Injection |
| IUPAC Name | Cysteinyl-Tyrosyl-Isoleucyl-Glutaminyl-Asparaginyl-Cysteinyl-Prolyl-Leucyl-Glycinamide acetate salt (systematic naming may vary with specific modifications and salt state) |
| Chemical Formula | C43H66N12O12S2 · xC2H4O2 (acetate salt composition depends on manufacturing ratio and final lyophilized product adjustment) |
| CAS Number | 50-56-6 (base compound, acetate salt may reference same parent number or variant based on global listing practices) |
| Synonyms & Trade Names | Oxytocin acetate; Pitocin (as a common trade-marked name in some markets); Synthetic oxytocin; Oxytocic peptide injection. Most regional pharmacopeias specify nonproprietary name plus salt form as labeling. |
| HS Code & Customs Classification | HS Code 3002.90 (Formulated peptide hormones for therapeutic use). Sub-classification at regional level may identify parenteral vs. bulk API; customs assessment often relies on proof of dosage form and intended use in import/export documentation. Bulk intermediates and final injectables are split by regulatory status in several jurisdictions. |
Oxytocin acetate intended for injection requires careful peptide synthesis via solid-phase or solution-phase technique, depending on target scale and regulatory region. Selection of raw materials is highly sensitive to peptide coupling efficiency, starting amino acid optical purity, and the acetate source used for final salt formation. Each production stage introduces risks for racemization, deamidation, or sulfhydryl oxidation, which are routinely controlled using process validation analytics.
Product grade is based on sequence homogeneity, peptide chain integrity, absence of sequence-related impurities, and controlled water and acetate content after lyophilization. Application needs for hospital use or pre-filled syringe vary by regional pharmacopeia monograph and pharmacopoeial reference standard. Bulk active ingredient destined for finishing may carry tighter limits on process-origin byproducts and total residual solvents than direct-use injectables, as downstream sterile filtration and fill-finish steps refine purity and host safety.
Release testing includes molecular characterization, peptide mapping, assay for content, microbiological controls, and osmolarity checks when formulated. Stringent control of batch consistency, through in-process monitoring and validation of the critical chain, supports reliable dosing. Finished product stability is influenced by residual moisture, container closure integrity, and dilution vehicle. Each property weighs on cold-chain logistics, shelf-release protocols, and clinical formulation development for intended regional use.
Manufacturing route and site determine risk points for particular impurity profiles. Internal criteria set the allowable limits for known peptide-related impurities, side-chain oxidation, and residual reagents. Release criteria always reference internal standards cross-validated by an external pharmacopeial method where possible.
Oxytocin acetate, as handled in commercial manufacturing, is processed to a white to off-white lyophilized powder or an aqueous solution depending on customer specification. Color can shift depending on excipient purity and processing environment. The finished injection displays no pronounced odor. Melting and boiling points do not apply as this product degrades before melting; handling at elevated temperatures is avoided to maintain peptide integrity. Density is determined by formulation parameters. Any deviation in color or clarity, such as visible particulates or excessive yellowing, triggers internal quality controls and investigation.
Stability relies on refrigeration and exclusion of light. Oxytocin acetate degrades through hydrolysis, oxidation, and deamidation. All manufacturing lots undergo accelerated stability studies for both active drug and potential breakdown products. Reactivity increases in alkaline or oxidative environments; hence, excipients and filling gases are selected for inertness. Shelf stability is defined through real-time aging studies on the exact dosage form.
The peptide dissolves readily in water and common saline carriers at neutral to mildly acidic pH. The finished injection is filtered to ensure particulate control. Preparation protocol specifies solvent grade, mixing time, and pH adjustment, always validated by purified water and class A glassware.
Specification varies by clinical or non-clinical grade and country-specific pharmacopeia alignment. Production batches are classified according to these standards with in-house reference lots set to the most stringent release criteria applicable to customer needs.
The primary concern in oxytocin acetate manufacturing involves related peptides, oxidized species, and acetic acid content. Impurities originate from raw peptide synthesis and downstream hydrolysis or oxidation. Limits are established by pharmacopeia or customer specification. Impurity trends get analyzed per campaign and trigger corrective actions if deviation from process capability occurs.
Release testing follows validated protocols: HPLC and mass spectrometry dominate for assay and impurity profiling, with microbiological sterility and endotoxin testing as critical requirements for injectable forms. The QC department tailors test suites to the regulatory market and customer specification.
Manufacturing begins with amino acid precursors sourced from audited suppliers. Peptide fragments and linking reagents must meet identity and purity specifications, supported by full CoA for each lot. The supply chain is subject to ongoing vendor qualification and risk assessment for traceability and contamination risk.
Large-scale oxytocin acetate production utilizes solid-phase peptide synthesis followed by cleavage and purification. Acetylation occurs in solution after sequence completion. The sequence assembly’s order and protection strategy are set based on critical side-chain reactivity observations made over repeated campaigns. Each reactor batch traces parameters such as coupling efficiency and resin loading.
Key control points include coupling time, reagent excess, and final deprotection conditions. The crude peptide undergoes preparative HPLC for bulk purification. Multiple purification steps are scheduled based on initial peptide analytics, with reprocessing permitted within validated limits. Final formulation allows for excipient customization, with in-process controls for pH, osmolality, and endotoxin burden.
Each lot follows comprehensive analytical testing including identity, assay, impurity profiling, and stability. Only batches passing all regulatory and customer-defined release parameters receive batch certification. Documentation includes full traceability, manufacturing record review, and QA final release inspection.
Most process deviations involve oxidation at methionine or cysteine residues, deamidation, or aggregation. Downstream modification potential includes PEGylation or labeling for advanced delivery forms, subject to specific customer development programs. All such modifications are validated against standard batches for impurity generation and process compatibility.
Assembly employs protected amino acids and acid/base catalysts under controlled temperature. The solid-phase approach allows for lowered reaction temperature to curb undesired side reactions. Precipitation and washing steps are carried out in organic solvents selected for waste management compatibility.
Process expertise includes options for salt exchange, peptide dimerization, or lyophilization modifications based on application demand. Generated derivatives or modified forms require new stability and impurity profiling protocols.
Finished oxytocin acetate injection requires constant refrigeration and protection from light. High humidity and oxygen exposure accelerate degradation. Final packaging is qualified for leachables, extractables, and UV transmittance as part of stability studies.
Primary containers must meet inertness requirements. Glass vials with teflon-lined stoppers and multi-layer IV bags show the least interaction and maximal retention of assay values during long-term storage.
Shelf life is assigned following ICH long-term and accelerated studies. Degradation appears as loss of potency and an increase in low-level peptide by-products. Quality control monitors each distribution batch for signs of precipitation, color shift, and loss of solution clarity, with any deviation flagged for recall assessment.
Classification, hazard, and precautionary labeling align with regional chemical safety regulations and are updated according to new toxicology findings. Oxytocin acetate received hazard statements based on its pharmacological action and injection route, with proper risk phrases noted in workplace safety training.
Manufacturing personnel avoid dermal and inhalation exposure with engineering controls and closed transfer. Accidental exposure calls for standard medical intervention protocols as reviewed every training cycle.
Toxicity data is application-driven and based on controlled delivery. Occupational exposure limits depend on the internal risk assessment rather than published values. All compounding and packaging steps implement point-source ventilation, and protective garments are worn according to risk of exposure. Waste is collected and destroyed as pharmaceutical hazardous material.
Manufacturing volumes for oxytocin acetate injection rely on campaign production, with scale adjusted per pharmaceutical grade demand forecasts. Large-scale batches draw from secure sourcing of peptide-grade starting materials and in-house lyophilization lines. In regions with high perinatal care requirements, prioritization of local tenders shapes near-term supply, especially where cold chain infrastructure restricts access.
Lead times fluctuate. A typical order, aligned with regulatory release and filled to match customer protocol, can require eight to twelve weeks from batch start, with expedited timelines possible for repeat batches from inventory. Minimum order quantities often reflect fill-finish batch size and packaging format. For clinical supply or comparator programs, MOQs follow regulatory submission batch size requirements, with larger MOQs for routine hospital supply contracts.
Choice of packaging significantly affects logistics. Common formats include sterile glass ampoules or vials in moisture-barrier secondary packaging. Regional regulations and logistics conditions dictate vial volume, carton configuration, and label language. Cold chain requirements impose additional protective layering for transit; stability studies drive allowable out-of-refrigerator time.
Temperature-controlled shipping is mandatory, typically shipped under validated, real-time monitored conditions. Payment terms follow established pharma industry conventions, favoring irrevocable LC, T/T in advance, or split-invoice arrangements to reduce customer risk attached to approval cycles and tender pricing. Import permit and CMO-specific documentation processes often lead to split-site deliveries and purpose-customized invoicing.
The cost of oxytocin acetate stems heavily from peptide synthesis grade starting materials and reagent purity. Bulk peptide manufacturing draws on protected amino acid derivatives, specialized coupling reagents, and high-grade solvents. Price points reflect market volatility for protected amino acid building blocks, especially when upstream supply faces raw material allocation limits or currency-driven re-pricing. Reagent prices for controlled substances and solvents with dual-use oversight tend to fluctuate seasonally with regional regulations and bulk commodity dynamics.
Price swings respond to global peptide precursor market constraints, supply-side regulatory interventions on key phenol and acetate reagents, and regional producer shutdowns tied to compliance audits. Seasonal force majeure events—especially those impacting major peptide synthesis hubs—push prices upward. Certification updates, especially for USP/Ph. Eur. and prequalification criteria, also introduce new cost layers and necessitate retesting or batch re-validation.
Grade, purity, and packaging certification drive the most meaningful price differentials. Products released under full ICH Q7 GMP with US/EU pharmacopeia compliance sustain higher cost structures relative to local or in-house hospital grade. Lyophilized format typically commands a premium over liquid ampoule due to added sterility, shelf-life, and handling validations. Carton and ampoule labeling certifications align with both final market and import permit requirements, raising release testing and documentation costs for multi-market eligible lots.
Oxytocin acetate faces concentrated demand from obstetric and maternal health programs. Supply cycles track government tender activity and seasonal birth rate fluctuations. Developed markets sustain steady procurement through hospital supply chains, while emerging economies implement periodic large-volume tenders, sometimes on a biannual basis. Key economies maintain strict batch-by-batch import certification, which can create temporary bottlenecks.
US market prices reflect compliance and serialization costs, with downward price pressure from group purchasing organizations and generic market entry. EU procurement policy emphasizes multi-vendor auctioning, occasionally causing short-term price swings tied to awarded contracts. Japan emphasizes domestic site certification, leading to higher cost recovery for documentation and validation. India and China leverage local production for volume pricing, though raw material price shock can spill over globally. Regional regulatory import cycles sometimes delay major shipments.
Forecasts through 2026 suggest continued cost sensitivity to regulatory escalation and supply chain shocks. Market analysts expect demand to rise in low-to-middle income regions. Price normalization depends on stabilized access to high-purity starting materials and uninterrupted cold chain logistics. Barriers to trade, sanctions, or raw material export controls remain principal risk factors for price volatility. Price gaps between full GMP and non-GMP route product will likely widen, with compliance-driven cost pass-through remaining sticky in highly regulated economies.
Forecasting draws on in-house batch production analytics, peer benchmarking from international procurement records, and import/export database tracking for relevant HS codes. Methodology accounts for regional regulatory changes, historical cost increases traced to raw material indexes, and reported disruptions in the active peptide producer landscape.
Recent years have seen regulatory authorities step up in-process inspection of peptide manufacturing, targeting data integrity and chain-of-custody documentation. In certain markets, process validation requirements tightened for injectable products, pushing costs and requiring new filings and continuous monitoring updates. Major tender rounds in Africa and Asia drive procurement focus toward multi-origin supply base diversification to mitigate export risk.
Stringent expectations from US FDA and EMA have prompted process upgrades for peptide purification and release test oversight, extending lead times and prompting ongoing investment in analytical capacity. Periodic harmonization updates in WHO prequalification and pharmacopoeial references remain drivers for re-validation activity in established production sites.
Manufacturers are prioritizing dual-sourcing strategies for critical raw materials and refining batch documentation systems for instant data traceability. Process robustness initiatives target impurity carry-over controls and in-process analytic feedback to narrow batch variability. Cold chain audit readiness and regulatory trend-tracking remain core to batch release and risk-abatement planning, especially for multi-market products where a single compliance shift impacts upstream planning and cost base.
Oxytocin acetate injection primarily finds its place in the fields of human and veterinary medicine. In obstetrics, clinicians rely on it to induce or augment labor and control postpartum bleeding. Some countries permit its use in veterinary obstetrics for similar indications in large animals. Regulatory conditions, permitted usage, and specification tolerance vary significantly worldwide, impacting both formulation and final grade requirements.
| Application | Recommended Grade | Regulatory Note | Comments |
|---|---|---|---|
| Human Pharmaceutical | Pharmaceutical USP/EP/BP/JP | Subject to official pharmacopoeial monograph and regulatory authority approval | Critical for drug formulation; strict control of peptide identity, purity, and bacterial endotoxin |
| Veterinary Formulations | Veterinary or Technical Grade (if permitted by law) | Check permitted specifications per region | Impurity profile and peptide content rely on animal safety requirements; in certain markets, only pharmaceutical grade is lawful |
| Research & Development | Research Grade | Not allowed for human or clinical animal use | Used for in vitro studies, analytical development, or non-clinical evaluation |
Key parameters for oxytocin acetate include peptide content, impurity profile, related peptides, residual solvents, heavy metals, bacterial endotoxins, and specific activity by biological assay. Tolerance levels align with pharmacopoeial standards for human grades, and flexibilities are negotiated for R&D purposes. Large-scale pharmaceutical batches focus on reproducibility and ultra-low bioburden. Veterinary formulations may accommodate wider impurity profiles but always defer to prevailing regulation and end-use risk assessments.
In production, any deviation in amino acid sequence, aggregation, or by-product carryover can compromise batch acceptance for clinical applications. Small analytical or non-clinical batches may tolerate higher impurity loads, with the understanding that such grades never enter regulated patient channels. Long-term storage stability often depends on both peptide purity and excipient compatibility defined per lot.
Define the target market and allowable route. Animal, human, or analytical needs dictate both regulatory and technical specifications. Human injection products demand the most stringent controls both during API manufacturing and in the formulation stage.
Assess the national pharmacopoeia (USP, EP, BP, JP) and local registration requirements for maximum impurity limits, allowable excipient traces, and certified manufacturing site documentation. Veterinary and research uses should cross-check relevant agency guidelines; many regions explicitly enforce pharmaceutical grade for all clinical applications.
Confirm the necessary level of peptide sequence purity, control of related peptides, and residual process impurities—such as solvents or by-products—because these define the achievable product grade. Clinical-grade oxytocin acetate targets the uppermost threshold for identity, minimal aggregate, and controlled endotoxin readings. Research and certain animal applications can tolerate wider impurity windows on a justified basis.
Calculate project volumes in line with required batch size and available production slot. Large-scale projects benefit from custom batch conditions and integrated quality control, while pilot or preclinical usage may be satisfied with smaller non-GMP grades. Budget allocation often tracks with regulatory complexity and analytical stringency.
Request a sample from the actual batch or process route intended for supply. Our in-house quality team can provide dosing, impurity, and microbiological testing data upon request. Users should always conduct in-house validation to confirm suitability of the chosen grade in their specific formulation context before committing to full-scale purchase.
Manufacturing Oxytocin Acetate Injection requires adherence to continual process review and international quality benchmarks to satisfy global market entrance criteria. Each production batch arises from API grade verification, with full traceability on raw material sourcing, change management, and process validation. Certificates aligning to ISO 9001 signal robust operational oversight, but injectable pharmaceuticals face additional scrutiny. Our dedicated injectable line uses validated cleaning, environmental monitoring, and batch segregation measures. Facility particulate and bioburden control aligns with GMP standards audited by health authorities in designated markets. Specific release testing follows pharmacopeial criteria or local regulatory pharmacopoeias for identity, potency, and absence of pyrogens or endotoxins.
Oxytocin Acetate Injection release rests on both in-house batch records and independent qualified person (QP) batch certification, especially for regulated pharmaceutical supply. Each lot undergoes certified testing for content uniformity, sterility assurance, and impurity profiling. In certain regions, product registration dossiers are compiled in CTD format for regulatory review, referencing master files for APIs and excipients as required. GMP certificates for finished dosage form manufacturing and primary packaging controls remain available for audit and customer verification. Any additional local regulatory registrations or pharmacopoeia confirmations required by territory or hospital tenders can be appended to the standard technical pack on request.
Comprehensive documentation tails each shipment, including batch-specific Certificate of Analysis, Certificate of Origin, and manufacturing process summary on request. For regulated markets, accompanying QA release documentation covers full test parameter disclosure. Stability reports and ongoing monitoring results can be submitted to support shelf life projection or logistics risk assessment. Process deviation records and investigation closures are maintained under QA system for reference in case of shipment quality disputes. For special projects or dossier submissions, technical personnel can supply validation data, elemental impurity risk assessments, and microbiological monitoring history.
Production planning for Oxytocin Acetate Injection relies on early forecasting and fixed slot manufacturing, suited to tender and contract supply cycles. Process trains are segregated from non-injectable operations to avoid contamination crossover. Advanced procurement of critical components like glass vials and stoppers backs up the formulated product pipeline, minimizing risk of supply chain disruption. Production windows and supply volumes adapt to customer project size and seasonal demand, allowing for both blanket orders and just-in-time delivery. Volume discounts or capped reservation fees can be negotiated for multi-year tender commitments or hospital group purchases.
Production throughput relates to equipment scale and validated cleanroom downtime. Empirical capacity figures shift with product mix, scheduled line maintenance, and regulatory inspection calendars. For framework agreements, supply capacity is confirmed based on validated batch size, historical yield, and agreed-upon lead time buffers. Business contingency plans involve alternate reagent supplier approval and lot traceability archiving for post-market surveillance. Supply risk can be further reduced by dual-sourcing of essential excipients or packaging components where pharmacopeial requirements permit.
Samples for evaluation follow an internal QA release, with records matching commercial batch workflows for full comparability. Requests can trigger supply of either development-stage or market-standard reference products, depending on the customer’s registration objective and region-specific pharmacopoeial alignment. Each sample dispatch includes technical bulletins, test summaries, and primary batch information. For regulatory filings, technical pre-approval may be arranged, with retention samples maintained per local rules for counter-testing or dispute resolution.
Cooperation adapts both to direct GMP supply and subordinate contract manufacturing, depending on customer regulatory requirements and volume targets. For smaller-scale, pilot, or clinical supply, dedicated production slots minimize interruption to commercial throughput. Long-term partners can negotiate rolling forecasts, adjustable minimum quantity commitments, and reconciliation periods based on downstream sales performance. Commercial contracts may leverage consignment inventory, shipping batch splitting, or reserved capacity agreements. All arrangements undergo periodic production review to adapt to new procurement regulations, registration renewals, or changing demand patterns across target markets.
Development teams actively monitor new synthesis routes and analytical methods to improve oxytocin acetate purity, batch consistency, and peptide stability in solution. R&D energy focuses on establishing low-endotoxin and low-aggregation protocols, as regulatory expectations increasingly demand tight impurity profiles. High-performance liquid chromatography and mass spectrometry now form standard analytical workhorses in process development, driving both in-process and release analytics.
While labor induction remains the primary medical use, pharmaceutical researchers explore applications in postpartum care beyond hemorrhage control, including potential adjunctive roles in lactation support and cesarean section protocols. Several centers also study oxytocin’s behavioral modulation in select neuropsychiatric investigations. Each of these routes brings distinct stability, formulation, and dose delivery challenges, especially for field or low-resource clinical environments.
Managing solution-state stability remains a key obstacle. Oxytocin acetate shows susceptibility to oxidation and deamidation during bulk synthesis and fill-finish operations. Manufacturers address this with strict control on raw material water content, the use of inert gas overlays, and microfiltration at final fill. Multi-stage purification combined with in-line process analytics reduces batch-to-batch drift in peptide form and impurity levels. Emerging freeze-drying and advanced lyoprotectant matrices enhance shelf stability, but require tailored reconstitution protocols validated for the end-use setting.
Forecasts point to steady global demand tied to ongoing birth rates and improvements in maternal care coverage. Government initiatives to reduce maternal mortality continue to support baseline usage in hospitals and clinics. Expansion into specialized postpartum care and research indications may increase demand among higher-grade formulations, especially in developed regions.
Process intensification now appears in peptide synthesis facilities, highlighting continuous or semi-continuous reactor platforms designed to offer both environmental and yield advantages. Adoption of green solvent systems for synthesis steps—and solvent recovery protocols in downstream stages—forms a technical response to increasing regulatory and community scrutiny. Deployment of digital batch monitoring, trace impurity tracking, and automated fill-finish lines supports both regulatory compliance and batch fidelity.
Production managers scrutinize solvent choices to reduce volatile organic compound emissions and avoid legacy chlorinated reagents. Greener counter-ion strategies remain under study, seeking to limit toxicological risk at trace levels. Peptide purifications now favor water-based chromatographic steps and minimize corrosive or persistent byproducts. Progress toward closed-loop water and solvent cycling remains slow but observable among larger GMP-focused sites. Waste minimization efforts track byproduct formation at each unit operation, with on-site treatment or certified third-party disposal for all hazardous waste streams.
Technical teams support customer projects through lifecycle consultation, including initial formulation, vial compatibility assessment, and dilution protocol advice. Support incorporates site-specific conditions, including water quality, available equipment, and local handling practices, to address risk factors that impact finished product performance.
Application engineers work closely with hospital pharmacies and clinical trial sponsors to recommend proper storage temperatures, handling limits, and allowed deviation time at ambient conditions. Site audits analyze receiving, storage, and cold chain compliance, especially where domestic infrastructure varies. Ongoing customer training targets common error points, such as incorrect reconstitution or suboptimal in-use periods for reconstituted solution.
Continuous post-shipment support maintains direct communication lines between QA, supply chain, and clinical user groups. Any deviation, complaint, or inquiry triggers root cause analysis with batch-level traceability. Complaint investigation teams coordinate lot recalls when dictated by risk assessment, applying GMP standards and regulatory notification requirements case by case. Replacement or follow-up batches are expedited according to supply availability, with full transparency regarding batch origin, manufacturing parameters, and test release data.
Our facility produces Oxytocin Acetate Injection through controlled peptide synthesis and precision formulation. Each batch runs under strict process parameters and full traceability. Our technicians manage every step from raw material handling to final aseptic filling. In-house reactors, high-performance liquid chromatography, and automated filling lines minimize risk of variance. Every output reaches finished vials under monitored temperature and humidity, supporting stable and predictable product profiles. The plant operates on validated procedures and undergoes regular third-party audits for compliance, batch integrity, and GMP alignment.
Oxytocin Acetate Injection supports pilot-scale and full-scale manufacture in diverse industrial segments. In pharmaceutical production, this active sustains formulation, vial filling, and finished dosage research. Many bulk drug developers integrate oxytocin acetate for contract API synthesis and downstream processing. Veterinary projects demand oxytocin as part of routine hormonal injectable portfolios. Animal health supply chains require robust supply, traceability, and consistent documentation, all supported under our manufacturing model.
Our laboratory controls specification for every batch using validated test protocols. Purity, identity, and potency target narrow tolerances governed by international pharmacopeial standards. Repeated in-process checks, automated HPLC, and spectrographic confirmation limit out-of-spec deviations. Release testing confirms each lot’s suitability for downstream formulation. Batch samples retain on-site for post-shipment investigation to address client technical reviews. Change control, deviation management, and full batch certification uphold both internal and customer compliance frameworks.
Oxytocin Acetate Injection ships from our facility in tamper-evident, transport-stable containers. Batch number, manufacturing date, and expiry details follow every shipment. We prepare large and small order volumes, including palletized consignment and high-throughput repack lines. Each dispatch receives QR-coded documentation for import review, customs handling, and consignee audit. Cold chain and refrigerant-pack cooling methods maintain product condition from our warehouse through to international distribution endpoints.
Industrial users interface directly with our technical team during project review and scale-up. We support documentation assembly, method validation, and on-site audit for high-volume customers. Our chemists and formulation experts answer process, analytical, and compatibility queries by case. We implement corrective actions and process improvement based on market and client feedback, all through engineering and laboratory resources under our own plant management.
Direct sourcing from our factory eliminates commercial intermediaries and lowers risk in the buying process. Manufacturers and distributors benefit from stable volume allocation, forecast-backed inventory, and negotiated delivery cycles. Our detailed traceability records and regulatory submission kits support both initial client qualification and long-term compliance. Procurement teams receive scheduled customer updates, technical bulletins, and recall readiness under standard operating agreements with our production unit. Project-based supply terms enable clients to match production windows and market launches with reliable, on-time delivery.
| Feature | Benefit for B2B Buyers |
|---|---|
| Controlled in-house synthesis | Tight quality consistency and minimized unknowns in downstream applications |
| On-site analytical validation | Rapid technical response and batch documentation for audits |
| Flexible output scheduling | Supply realignment for urgent, cyclical, or project-based demand |
| Direct technical support | Single point of contact for formulation and compliance requirements |
| End-to-end packaging and dispatch | Clear chain of custody, global shipment compatibility |
Oxytocin Acetate Injection produced under direct factory control delivers value for pharmaceutical, veterinary, and industrial buyers seeking long-term supply partnerships. Every batch reflects technical rigor and commercial reliability from synthesis to shipment.
Oxytocin Acetate Injection commonly serves as an essential therapeutic agent in obstetrics and gynecology, playing a pivotal role in managing labor and postpartum care. As the producer, we know clients rely on explicit details regarding concentration and purity to guide clinical and pharmaceutical formulation decisions, regulatory submissions, and patient safety evaluations. Our technical expertise stems from in-house synthesis, rigorous quality assurance, and regulatory compliance throughout production and batch release.
For Oxytocin Acetate Injection, the established international reference for concentration is 10 International Units (IU) per milliliter, which aligns with global pharmacopeial standards. This means every milliliter of our solution contains 10 IU of active oxytocin acetate, translating to approximately 16.7 micrograms of the peptide. This concentration optimizes clinical effect while offering accurate dose control in both institutional and outpatient settings. Our batch records and certificates of analysis reflect these figures, which our laboratory validates using qualified analytical equipment and validated methods such as HPLC and biological assay. We provide full traceability for every lot released.
Achieving pharmaceutical-grade purity requires control at every processing stage. Our oxytocin acetate maintains a peptide purity of not less than 98% by area normalization, measured using robust chromatographic techniques. All related peptide impurities, solvent residues, and microbial counts fall within established thresholds. We conduct thorough analysis to ensure bioburden, endotoxin, and particulate levels meet stringent injectable guidelines. Our manufacture takes place in classified cleanrooms, with environmental monitoring records available for audit.
No detectable levels of heavy metals or bacterial endotoxin are present beyond accepted pharmacopoeial limits. Our aseptic filling and process validation underpin sterility assurance, with batch release permitted only after passing all sterility and pyrogenicity tests. We implement double-coded sample retention and reserve testing for pharmacovigilance or post-market needs.
Peptide APIs like oxytocin acetate are prone to degradation due to temperature, light, and pH. To mitigate risk, production employs lyophilization and nitrogen blanketing, and we ship under validated temperature-controlled logistics. Storage in well-sealed glass containers guards against leaching. Our cold chain monitoring runs from factory to end user—nonconforming shipments are not released. These efforts preserve potency and reduce degradation products, which can impact both safety and therapeutic effect.
Clients, regulators, and import authorities all expect unwavering transparency. We provide full batch documentation, including certificates of analysis, process validation reports, and current Good Manufacturing Practice (cGMP) certificates as relevant to the destination market. Our technical team accommodates requests for quality agreements, impurity reference standards, and data supporting stability or risk assessment, especially for markets with evolving compliance requirements. Our analytical data backs every batch, and technical queries connect directly to our in-house scientists—no intermediaries or guesswork.
Our ongoing investment in analytical instrumentation, staff training, and process automation reduces batch variability and strengthens reproducibility. We review every deviation, jointly with quality assurance and production managers, to drive corrective action and prevent recurrence. This results in sustained quality, matched only by transparency and accountability in every delivery. Clients receive exactly what our certificate states, validated by independent third-party results if required by contract.
Oxytocin Acetate Injection deserves this level of care. Every vial we produce embodies experience, technical mastery, and commitment to safe, high-quality therapy for front-line healthcare workers around the world.
Oxytocin Acetate Injection stands as a critical pharmaceutical used by hospitals, clinics, and compounding pharmacies. Bulk procurement involves both strict production controls and a disciplined manufacturing workflow to meet regulatory and quality demands. Many clients ask about minimum order quantity (MOQ) and reliable lead times when planning procurement for essential medicines like this. We want to clarify our process and the reasoning behind it, drawing on our direct experience with production and large-scale supply.
As the manufacturer, we balance both batch size, regulatory protocols, and resource allocation in setting our minimum orders. Oxytocin is a peptide hormone with special handling and strict cold-chain requirements. Our standard MOQ for bulk is set at a level that ensures both production efficiency and product stability. Producing smaller volumes creates excessive wastage and, importantly, intensifies per-unit costs—not ideal for clients or us. Higher batch volumes safeguard both cost-efficiency and batch consistency, directly benefiting end users who count on predictable supply and quality. Keeping orders above a certain threshold enables us to maintain the sterility and traceability expected from a dedicated industrial producer.
Lead time is not just a supply chain term; it represents accumulated experience in raw material qualification, peptide synthesis, sterile formulation, fill-finish, quality testing, and shipment. Unlike commodity chemicals, Oxytocin Acetate requires tightly controlled synthesis protocols, extended in-process testing, and validated sterilization. Each batch undergoes full in-house analysis to verify peptide identity and potency. This extra care stretches timelines, but it guarantees that the end product meets clinical standards. As a manufacturer, we plan production schedules based on confirmed orders and regulatory paperwork, with the average lead time for bulk Oxytocin Acetate Injection generally ranging from several weeks to a few months after receipt of the purchase order and all necessary licensing. Complex regulatory environments or custom labeling requests on client orders can impact timing further, as does transport arrangement for temperature-sensitive medicines.
We listen closely to our customers’ purchasing cycles, which range from government contract bulk tenders to private healthcare group demand spikes. Experience teaches that good forecasting from both sides supports supply continuity. Planning purchases to allow us to aggregate orders improves production efficiency and helps avoid rushed, risk-laden shipments. Our logistics and compliance teams coordinate proactively with clients, recognizing the absolutely critical nature of timely delivery in the healthcare supply chain. For large-scale buyers, early engagement in the procurement cycle allows us to align batch releases, qualification, and shipping windows for uninterrupted supply. Our network of cold-chain logistics partners supports compliant, documented delivery direct to client facilities.
Transparent communication on expected volumes and delivery dates supports both contract and ad-hoc procurement. By sharing demand forecasts early, our clients get the benefit of optimized batch scheduling and priority in upcoming production slots. Our on-site technical and regulatory specialists advise on license paperwork and can expedite documentation for streamlined shipping. In cases where emergencies arise or projects demand higher flexibility, we maintain limited stock of critical vials for rapid response.
Our role as the direct manufacturer carries both responsibility and a commitment to honest dialogue with buyers. Meeting expectations on MOQ and lead time means integrating production realities with end-user needs—always guided by product safety, quality, and reliability. We continue refining our processes and communication so that partners can plan confidently, even in an environment where margin for error does not exist.
In manufacturing Oxytocin Acetate Injection, temperature control during both storage and transit takes priority. The molecule’s sensitivity to heat and light calls for dedicated solutions from production line to end user. Industry standards highlight the need for a strict cold chain, and we have seen firsthand the impact even brief temperature excursions can have on peptide products.
Our technical team designed logistics flows from scratch, guided by real stability data on Oxytocin Acetate. In our standard practice, all finished vials leave our filling suite under validated 2–8°C controlled conditions. Every shipping container includes temperature logging, and every leg of the route uses actively monitored refrigeration. The decision to ship only with specialized partners comes from direct experience. Personnel training covers proper handling from dock to delivery, as even an hour outside the prescribed range risks product degradation.
Recent news coverage has questioned whether medical manufacturers consistently maintain compliant cold chain for biologic injectables. As a primary producer, we can speak directly to regulatory routine. Our compliance protocols match or surpass the specific requirements issued by health authorities in our shipping markets. This includes GDP guidelines, chain-of-custody documentation, and real-time temperature tracking. Audit trails allow our customers to review each step of the journey for every batch number shipped.
Local regulations almost always build on the core global standards but often have additional layers: labeling in native languages, batch release by local QP, import licenses, and customs documentation. Our regulatory affairs team coordinates batch-specific documentation, ensuring clearance without delay. This step eliminates storage periods at border warehouses, where cold chain breaks most frequently occur.
The consequences of even minor non-compliance are costly. Degraded product means lost trust, recall expenses, wasted active pharmaceutical ingredient, and above all risk to patient safety. We have invested in process control for a reason. Manufacturing at pharmaceutical GMP level, maintaining QA/QC oversight, and using automated environmental monitoring helps us avoid issues associated with many third-party shipped pharmaceuticals.
Solutions do not appear overnight. Technology upgrades—advanced insulated shippers, real-time tracking sensors, predictive route planning—address the cold chain at each stage. We partner with logistics providers who support direct-to-hospital or pharmacy delivery in many regions to cut storage intervals. Our post-shipment confirmation service lets customers verify logged temperature data against accepted local standards.
In the current regulatory landscape, ignoring cold chain and documentation requirements is not an option for manufacturers who value quality and safety. The risks—from loss of market license to direct harm—are real. Our experience shows that consistent results take investment in controlled environments, partnerships, documented procedures, and regular audits of both staff and systems. From synthesis to final administration, we uphold the integrity of every vial of Oxytocin Acetate Injection we produce.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
